LENZ THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
LENZ THERAPEUTICS, INC. (LENZ) reported Increase (Decrease) in Accrued Liabilities of -$7.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$5.11M, a 290.03% decline year-over-year.
- LENZ THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$2.11M.
- LENZ THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $5.03M, a 287.44% increase year-over-year.
- LENZ THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $4.46M, a 518.45% increase year-over-year.
- LENZ THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $10.97M.
- LENZ THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was -$7.46M, a 195.85% decline from fiscal 2023.
- LENZ THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $7.78M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$7.22M 10-Q · filed 2026-08-11 | -$2.19M derived: sum of 3 quarters · filed 2026-08-11 | $2.26M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$2.11M 10-Q · filed 2026-05-11 | $2.92M derived: sum of 2 quarters · filed 2026-05-11 | $7.37M derived: sum of 3 quarters · filed 2026-05-11 | $10.06M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $9.49M derived: sum of 2 quarters · filed 2026-03-24 | $12.18M derived: sum of 3 quarters · filed 2026-08-11 | $10.97M 10-K · filed 2026-03-24 |
| 2025-09-30 | $4.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.15M derived: sum of 2 quarters · filed 2026-08-11 | $5.95M 10-Q · filed 2025-11-05 | $7.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.49M 10-Q · filed 2026-08-11 | $2.79M derived: sum of 3 quarters · filed 2026-08-11 | $3.51M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$1.20M 10-Q · filed 2026-05-11 | $96.00K derived: sum of 2 quarters · filed 2026-05-11 | $817.00K derived: sum of 3 quarters · filed 2026-05-11 | -$1.44M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $2.02M derived: sum of 2 quarters · filed 2026-03-24 | -$234.00K derived: sum of 3 quarters · filed 2026-03-24 | -$7.46M 10-K · filed 2026-03-24 |
| 2024-09-30 | $721.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.53M derived: sum of 2 quarters · filed 2025-11-05 | -$8.76M 10-Q · filed 2025-11-05 | -$7.14M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$9.48M 10-Q · filed 2025-07-30 | -$7.86M derived: sum of 3 quarters · filed 2025-07-30 | -$4.53M derived: sum of 4 quarters · filed 2025-07-30 |
| 2024-03-31 | -$7.23M 10-Q · filed 2025-05-07 | -$5.61M derived: sum of 2 quarters · filed 2025-05-07 | -$2.27M derived: sum of 3 quarters · filed 2025-05-07 | $705.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $4.95M derived: sum of 2 quarters · filed 2025-03-19 | $7.93M derived: sum of 3 quarters · filed 2025-03-19 | $7.78M 10-K · filed 2025-03-19 |
| 2023-09-30 | $3.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $6.32M derived: sum of 2 quarters · filed 2024-11-06 | $6.17M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $2.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.83M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$148.00K 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |